Industry Focus

We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust.

Thanks to Slack for supporting The Motley Fool.  Learn more at slack.com.

Direct download: 20170517_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST

1